# Simulations Plus, Inc. (SLP) Stock Analysis: Evaluating the Healthcare Software Specialist with 7.5% Revenue Growth

- Link: https://www.directorstalkinterviews.com/simulations-plus-inc-slp-stock-analysis-evaluating-the-healthcare-software-specialist-with-7-5-revenue-growth/4121259582
- Published: 2026-08-07T10:10:36+01:00
- Author: Madison Wilson

Simulations Plus, Inc. (NASDAQ: SLP) stands out in the healthcare sector as a niche
player specializing in drug discovery and development software. With a market capitalization
of $370.92 million, the company is a key player within the health information services
industry in the United States. Leveraging artificial intelligence and machine learning
technologies, Simulations Plus offers a suite of products designed to predict molecular
properties, aiding pharmaceutical and biotechnology companies in their research 
and development efforts.

The company’s stock currently trades at $18.34, within its 52-week range of $11.36
to $20.84, and has shown no recent price change. Despite the lack of P/E and PEG
ratios, indicating potential volatility or growth challenges, the forward P/E of
20.78 suggests some level of expected earnings growth over the next period. Simulations
Plus also boasts a respectable free cash flow of $18.4 million, underscoring its
capacity to reinvest in its business or weather economic downturns.

SLP’s revenue growth of 7.5% is a highlight, particularly in a sector driven by 
innovation and long-term R&D investments. The company’s EPS stands at $0.40, with
a return on equity of 6.17%, pointing to a moderate level of efficiency in converting
equity into profit. Investors should note the absence of dividend yield, which aligns
with the company’s focus on reinvestment and growth rather than shareholder payouts.

Analyst sentiment towards Simulations Plus is predominantly neutral, with five hold
ratings and no buy or sell recommendations. The average target price of $17.25 suggests
a potential downside of 5.94% from the current price, implying that the stock may
be slightly overvalued at present levels. However, its technical indicators, including
a 50-day moving average of $17.75 and a 200-day moving average of $16.23, indicate
a stable upward trend, given the current price exceeds both averages. An RSI of 
53.64 suggests the stock is neither overbought nor oversold, maintaining a balanced
position in the market.

Simulations Plus operates through two main segments: Software and Services. The 
flagship product, GastroPlus, along with DDDPlus and MembranePlus, provides predictive
capabilities for drug absorption, pharmacokinetics, and pharmacodynamics. The company
also offers specialized products like DILIsym and NAFLDsym, which are crucial for
understanding complex biological processes. Additionally, Simulations Plus provides
consulting services, enhancing its value proposition to the pharmaceutical and biotechnology
sectors.

In the rapidly evolving landscape of healthcare technology, Simulations Plus is 
uniquely positioned with its robust portfolio of predictive and simulation software,
catering to a diverse clientele, including academia and regulatory agencies. The
company’s strategic focus on AI and machine learning positions it well for future
advancements in drug discovery and development.

Investors considering Simulations Plus should weigh the company’s innovative edge
and growth potential against its current valuation and market sentiment. As the 
healthcare sector continues to embrace technology-driven solutions, Simulations 
Plus remains a compelling watchlist candidate for those seeking exposure to the 
intersection of healthcare and advanced software solutions.

Share on:
